|

Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)

RECRUITINGN/ASponsored by University of Virginia
Actively Recruiting
PhaseN/A
SponsorUniversity of Virginia
Started2025-11-20
Est. completion2026-08
Eligibility
Age21 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07213648

Summary

The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.

Eligibility

Age: 21 Years+Healthy volunteers accepted
Inclusion Criteria:

* Clinical diagnosis of Huntington's disease or Parkinson's disease (genetic diagnosis of HD also acceptable)
* With anxiety symptoms (NeuroQoL Anxiety ≥12)

Exclusion Criteria:

* Cognitive decline precluding ability to consent or complete the intervention (MoCA 5 min/telephone ≤11)
* Unable to read and understand English
* Does not have regular access to an internet-connected device, capable of downloading and installing the mobile application (i.e., tablet or iPhone running iOS 10 or later or an Android phone running Android 5.0 or later)
* Not located in the USA
* \<21 years old
* Active suicidality based on the answer "yes" to questions 4, 5, or 6b of the Columbia-Suicide Severity Rating Scale (Screen version)

Conditions3

AnxietyHuntington DiseaseParkinson Disease

Locations1 site

Univeristy of Virginia School of Nursing
Charlottesville, Virginia, 22903
Jessie Gibson, PhD, RN434-924-0107MindTrailsMovement@uvahealth.org

Browse More Trials

Anxiety trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.